Therefore, we propose that COL11A1 inhibitors have high therapeutic potential in simultaneously affecting EMT/CSC properties in pancreatic cancer, thereby suppressing the migration and invasion of cells, which provides an additional means for implementing conventional therapy. The gene discussed is COL11A1; the disease is pancreatic neoplasm.